Patients with advanced colorectal cancers are needed for a study to research an experimental drug in comparison to chemotherapy

UVA Tracking #
Principal Investigator
Paul R Kunk
Sallie Mannen
Contact Email
Contact Phone
Official Trial Title
A phase 3, open-label, randomized study of futibatinib versus germcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced cholagiocarcinoma harboring FGFR2 gene rearrangements (FOENIX-CCA3)
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, have advanced colorectal cancer, and have not had another treatment for their cancer, yet. The purpose of this study to evaluate an experimental drug (futibatinib) vs. chemotherapy drugs (cisplatin + gemcitabine) in patients with advanced colorectal cancer. The safety and effects of the experimental drug will be evaluated for this study.

Participation is approximately up to 3 years of drug treatment, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.

Additional information can be found here:


$50 per study visit. Reimbursement: Up to $175 for hotel stays per night